260 related articles for article (PubMed ID: 21068133)
1. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
Chen L; Yuan YF; Li Y; Chan TH; Zheng BJ; Huang J; Guan XY
Gut; 2011 Apr; 60(4):534-43. PubMed ID: 21068133
[TBL] [Abstract][Full Text] [Related]
2. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice.
Li Y; Chen L; Chan TH; Liu M; Kong KL; Qiu JL; Li Y; Yuan YF; Guan XY
Gastroenterology; 2013 Jan; 144(1):179-191.e4. PubMed ID: 23022495
[TBL] [Abstract][Full Text] [Related]
3. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
4. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
5. CHD1L promotes tumor progression and predicts survival in colorectal carcinoma.
Ji X; Li J; Zhu L; Cai J; Zhang J; Qu Y; Zhang H; Liu B; Zhao R; Zhu Z
J Surg Res; 2013 Nov; 185(1):84-91. PubMed ID: 23746766
[TBL] [Abstract][Full Text] [Related]
6. Translationally controlled tumor protein induces mitotic defects and chromosome missegregation in hepatocellular carcinoma development.
Chan TH; Chen L; Liu M; Hu L; Zheng BJ; Poon VK; Huang P; Yuan YF; Huang JD; Yang J; Tsao GS; Guan XY
Hepatology; 2012 Feb; 55(2):491-505. PubMed ID: 21953552
[TBL] [Abstract][Full Text] [Related]
7. FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
Fang F; Yang L; Tao Y; Qin W
Cancer; 2012 Jan; 118(1):134-46. PubMed ID: 21713761
[TBL] [Abstract][Full Text] [Related]
8. Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin.
Ni W; Chen B; Zhou G; Lu C; Xiao M; Guan C; Zhang Y; He S; Shen A; Ni R
J Cell Biochem; 2013 Sep; 114(9):2120-30. PubMed ID: 23553841
[TBL] [Abstract][Full Text] [Related]
9. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
10. Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival.
Chen L; Hu L; Chan TH; Tsao GS; Xie D; Huo KK; Fu L; Ma S; Zheng BJ; Guan XY
Hepatology; 2009 Jul; 50(1):122-9. PubMed ID: 19441106
[TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
[TBL] [Abstract][Full Text] [Related]
12. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU.
Zhao J; Zhang X; Shi M; Xu H; Jin J; Ni H; Yang S; Dai J; Wu M; Guo Y
Hepatology; 2006 Jul; 44(1):205-15. PubMed ID: 16799960
[TBL] [Abstract][Full Text] [Related]
13. Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.
Jiao J; Hong S; Zhang J; Ma L; Sun Y; Zhang D; Shen B; Zhu C
Cancer Lett; 2012 Jul; 320(1):96-103. PubMed ID: 22313545
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis.
Zhao J; Dong L; Lu B; Wu G; Xu D; Chen J; Li K; Tong X; Dai J; Yao S; Wu M; Guo Y
Gastroenterology; 2008 Sep; 135(3):956-68. PubMed ID: 18555021
[TBL] [Abstract][Full Text] [Related]
16. Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice.
Zhang R; Ma L; Zheng M; Ren J; Wang T; Meng Y; Zhao J; Jia L; Yao L; Han H; Li K; Yang A
Cancer Gene Ther; 2010 Apr; 17(4):275-88. PubMed ID: 19876077
[TBL] [Abstract][Full Text] [Related]
17. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
[TBL] [Abstract][Full Text] [Related]
18. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
Chen HC; Jeng YM; Yuan RH; Hsu HC; Chen YL
Ann Surg Oncol; 2012 Jun; 19(6):2011-9. PubMed ID: 22146883
[TBL] [Abstract][Full Text] [Related]
19. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
20. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance.
Wong N; Yeo W; Wong WL; Wong NL; Chan KY; Mo FK; Koh J; Chan SL; Chan AT; Lai PB; Ching AK; Tong JH; Ng HK; Johnson PJ; To KF
Int J Cancer; 2009 Feb; 124(3):644-52. PubMed ID: 19003983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
